Dr Marie McAvoy joins NanoSyrinx as Chief Scientific Officer

NanoSyrinx, a biotech company using synthetic biology approaches to develop a new modality for the targeted intracellular delivery of biologic therapeutics, has strengthened its management team with the appointment of Dr Marie McAvoy as its Chief Scientific Officer.

Dr McAvoy joins NanoSyrinx from GSK where she was Senior Director in the Oncology Cell Therapy Research Unit. She brings more than 20 years of drug discovery experience in biotech and large pharma companies, having worked on vaccines, biopharmaceuticals and cell and gene therapies, and led programmes from target identification to phase 2b clinical trials.

NanoSyrinx is the first company to engineer protein ‘nanosyringes’ as a cell-selective non-viral peptide and protein delivery system. This technology provides an important solution by unlocking previously inaccessible intracellular targets in order to improve efficacy and minimise potential side effects of both existing and new treatments.

Following the company’s recent, oversubscribed, £6.2m seed financing round, NanoSyrinx is focused on delivering a pipeline of proof of concept and preclinical development candidates, in both ex vivo and in vivo therapeutic and cell and gene editing applications. Dr McAvoy’s extensive technical expertise and management experience will underpin these efforts.

Dr Marie McAvoy said:

“I’m delighted to be joining the NanoSyrinx team and leading their candidate discovery programme. NanoSyrinx’s novel method for intracellular therapeutic delivery will significantly improve the efficacy of new drugs and this important mission has my full support. This is a critical time for the company to strengthen its pipeline and I’m excited to be part of it.”

Dr Joe Healey, Chief Executive Officer at NanoSyrinx, said:

“We are over the moon that Dr Marie McAvoy is joining us, and this is certainly a very exciting time for NanoSyrinx. With Marie’s expertise, we can move ahead with the drug-discovery pipeline for our nanosyringes and accelerate our progress towards their clinical application.”

For further information please visit the following links:
On SciAd Newswire: https://www.sciadnewswire.com/news/707/nanosyrinx-appoints-rd-industry-leader-dr-marie-mcavoy-chief-scientific-officer

Follow us on social media to stay up to date!

Twitter: @NanoSyrinx


Read more news

NanoSyrinx highlighted in Cell Trends

Our CEO Joe Healey was recently invited to write a piece for Cell Trends’ “Industry Highlights”, which is now available online here. These articles offer short reads about up and coming companies and technologies that are making waves in the industry. NanoSyrinx is delighted to have had the opportunity to tell our story. The article […]

Read more

NanoSyrinx CEO Joe Healey appointed to DSIT’s Engineering Biology Steering Group

In 2023, the UK Government published the “National Vision for Engineering Biology”. The report highlighted the ambitions of the UK to be a world leader in the Engineering Biology (a.k.a. Synthetic Biology) sector, and described how £2BN would be put to work over the next decade, cementing the UK’s position at the front of the […]

Read more

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast. Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, […]

Read more